SS Innovations Appoints Interim CFO Amid NASDAQ Listing

Introduction

SS Innovations International Inc. (Nasdaq: SSII) is a medical technology company specializing in surgical robotics. Founded in 2015 by Dr. Sudhir Srivastava, the firm develops the proprietary SSi Mantra robotic system, aimed at decentralizing advanced surgical procedures and improving access in underserved regions. Headquartered in Gurugram, Haryana, and listed on NASDAQ since April 25, 2025, SS Innovations maintains operations in India, the United States, and select international markets.

Corporate Structure

As of June 2025, SS Innovations employs between 201 and 500 professionals, including engineers, scientists, and clinicians. The executive team is led by Founder and Chairman Dr. Sudhir Srivastava, a recognized robotic cardiac surgeon, and includes Dr. Frederic Moll. On May 1, 2025, the company appointed Arvind Palaniappan as Interim Chief Financial Officer, succeeding Anup Sethi. SS Innovations operates research and development, manufacturing, and training facilities to support multi-specialty applications, including cardiac, urology, gynecology, thoracic, and general surgery.

Developments and News

• September 23, 2024: SS Innovations announced the completion of its 2,000th robotic surgery using the SSi Mantra system, which included 123 cardiac cases, primarily in India and Nepal.
• May 2, 2025: The company announced the transition to Arvind Palaniappan as Interim CFO, with Anup Sethi remaining as an advisor during the search for a permanent successor.
• April 25, 2025: SS Innovations listed its common stock on NASDAQ, previously trading on the OTC under the ticker SSII.
• June 3, 2025: Dr. Sudhir Srivastava officiated the opening bell ceremony at the NASDAQ MarketSite in Times Square.
• May 28–31, 2025: Dr. Srivastava presented the Kit V. Arom Lecture at the 25th Annual ISMICS Conference in Istanbul, highlighting the SSi Mantra platform.
• First half of 2025: Completion of the first SSI Mantra-assisted liver wedge resection at Shailya Hospital in Ahmedabad, along with the first robotic cardiac surgery in South America performed by Dr. Juan Zuñiga’s team in Guayaquil, Ecuador.

Financial and Strategic Aspects

On June 17, 2025, SS Innovations shares closed at $5.0481, showing an increase of 47.61% with a trading volume of 113,879. Following its NASDAQ listing, the company's market capitalization increased. The SSi Mantra system has received approval from the Indian CDSCO and is in the process of obtaining FDA and CE Mark clearances, which are expected in the second half of 2025. A Form 8-K filed on June 16, 2025, detailed executive leadership changes and ongoing strategic initiatives, while earlier 8-K filings in early June addressed Regulation FD disclosures and business updates. SS Innovations focuses on modular design, cost-effectiveness, and multi-arm versatility to enhance its position in the surgical robotics sector.

Market Position and Industry Context

The global surgical robotics market is projected to grow at a compound annual growth rate exceeding 15% over the next five years. SS Innovations targets emerging and underserved markets by offering a more affordable, modular alternative to established platforms. Its strategy involves deployment in Tier 2 and Tier 3 cities, comprehensive training programs, and clinical partnerships to increase adoption. By emphasizing affordability and decentralizing access to advanced surgical technologies, SS Innovations aims to capture market share among healthcare providers seeking versatile robotic solutions.

tl;dr

On May 2, 2025, SS Innovations appointed Arvind Palaniappan as interim CFO following its April 25 NASDAQ listing. As of September 23, 2024, the SSi Mantra system has completed over 2,000 procedures and is awaiting FDA and CE Mark approvals in the second half of 2025. Key milestones include the NASDAQ opening bell on June 3, 2025, and the execution of pioneering surgeries in India and Ecuador. Future growth will depend on regulatory clearances and market expansion in emerging regions.